Bioscience Speculation Play
For "Speculation Friday," Cramer highlighted
, which is developing a third-generation DNA sequencing technology for a host of applications.
Cramer said Pacific Biosciences is not yet profitable and likely won't be until the end of 2014, however given that the $1.2 billion DNA sequencing business is growing at 20% to 25% annually, the upside for the company is sizable.
Cramer explained that when the human genome project first sequenced human DNA, the process took 13 years and cost $13 billion. The same process today costs just $10,000 and that cost is expected to fall to just $2,000 as newer technology, like that of Pacific Biosciences, comes into fruition.
Cramer said the beauty of Pacific Bioscience's technology is that it can be used for any DNA, not just human DNA. That means the sequencer can be used for agriculture for genetically modified seeds and a host of other applications outside of just the health care arena.
Better still, Pacific Biosciences not only makes money as it sells one of its sequencing machines, the company also makes money selling consumables and service after the sale as well.
Cramer said every portfolio should have a little speculation in it, and Pacific Biosciences might offer that bit of excitement your portfolio is looking for.
Big Blue's Ambitious Plans
Rounding out his series on company's with great five-year plans for growth, Cramer highlighted
(IBM - Get Report)
, a stock which he owns for his charitable trust,
Action Alerts PLUS
. IBM outlined its five-year plan in May 2010 and has already seen a 19% gain since Cramer first got behind that plan in October, 2010.
IBM's plan calls for the company to deliver a whopping $100 billion in free cash flow over the next five years. The company plans to use $50 billion of that cash on stock buybacks, $20 billion on acquisitions and another $20 billion on its 1.8% dividend yield.
IBM says it can grow revenues by just 2% to 3% a year, but still deliver increased earnings growth of 71% by continuing to do what it does best, solve customers' information technology problems.
Cramer said IBM's plan is ambitious, but achievable. He said the company has a terrific CEO and track record of getting things done, so there's no reason to doubt the company now. Shares of IBM trade at just 11.3 times earnings despite the company's 11% long-term growth rate. Cramer said IBM is a company at the right place at the right time and its shares are a buy.